XSHE
002900
Market cap604mUSD
Oct 09, Last price
12.91CNY
1D
0.94%
1Q
31.73%
IPO
-32.34%
Name
Harbin Medisan Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
5.17
EPS
—
Div yield, %
1.56%
Shrs. gr., 5y
0.44%
Rev. gr., 5y
-3.55%
Revenues
789m
-30.29%
Net income
-340m
L
CFO
-36m
L
Dividend
May 29, 20250.2 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1996 and based in Harbin, China, Harbin Medisan Pharmaceutical Co., Ltd. specializes in the full lifecycle of chemical pharmaceutical products within China, from research and development to manufacturing and sales. The company's comprehensive product line includes both active pharmaceutical ingredients (APIs) and various finished drug forms. Its offerings address a wide array of medical conditions, encompassing treatments for neurological, cardiovascular, and musculoskeletal systems, systemic infections, nutritional support, fluid balance, and other general healthcare needs.
Key people
Jianfei Qin
Chairman of the Board, President · since 2023
Zhicheng Zhao
Finance Director · since 2025
Yanfei Liang
Vice President, Secretary of the Board, Director · since 2023
Qingji Fan
Deputy General Manager · since 2019
Bing Han
Deputy General Manager · since 2021
Jiantao Qin
Director · since 2019
Zhen Qin
Executive President, Director · since 2025
Zihong Zhu
Staff Elected Director · since 2025
Guomin Zhuge
Vice Chairman of the Board · since 2013
Independent Director · since 2022
Dong Wang
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||